Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

[This corrects the article DOI: 10.3389/fphar.2021.634477.].


Corrigendum on
Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes by Gasperetti, T., Miller, T., Gao, F., Narayanan, J., Jacobs, E. R., Szabo, A., Cox, G. N., Orschell, C. M., Fish, B, L., and Medhora, M. (2021). Front. Pharmacol. 12:634477. 10.3389/fphar.2021.634477 In the original article, there was a mistake in Figures 2, 4, 9 as published. "The y axis was incorrectly labeled as 0-100, whereas it should be labeled 100-0." The corrected Figures 2, 4 The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Conflict of Interest:
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Copyright © 2021 Gasperetti, Miller, Gao, Narayanan, Jacobs, Szabo, Cox, Orschell, Fish and Medhora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. FIGURE 4 | Kaplan-Meier plot representing morbidity from DEARE up to 120 days post 13 Gy partial body irradiation with one hind limb shielded (legout PBI). The triple combination (TC, consisting of PEG-hG-CSF, PEG mGMCSF and PEG hIL-11), vehicle or PEG-hG-CSF (BBT-015) were given subcutaneously 24 h post leg-out PBI (designated by PEG-HGF) and the ACE inhibitor, lisinopril, was started in the drinking water 7 days post irradiation (24 mg m −2 d −1 ). All irradiated rats were given supportive care with subcutaneous hydration (40 ml kg −1 d −1 ) and enrofloxacin (10 mg kg −1 d −1 ) from days 3-7 to 2-14, respectively,. There was trend in lower morbidity in irradiated rats that received TC + lisinopril compared to irradiated rats that received PEG-hG-CSF, but this was not significant (p 0.07). Shaded (gray) areas represent the timing for the lung and renal injuries.
FIGURE 9 | Kaplan-Meier plot representing morbidity from DEARE up to 160 days post 13 Gy partial body irradiation with one hind limb shielded (legout PBI). The triple combination (TC, consisting of PEG-hG-CSF, PEG mGMCSF and PEG hIL-11), or vehicle were given subcutaneously 24 h post PBI and the ACE inhibitor, lisinopril, was started in the drinking water 7-days post-irradiation. All irradiated rats were given supportive care. All irradiated rats that received TC + lisinopril survived to 160 days as compared to 100% morbidity for irradiated rats that received TC alone (p < 0.0001). Survival of irradiated rats given vehicle + lisinopril was over 90%, while irradiated rats given only the vehicle were moribund before 160 days. Shaded (gray) areas represent the timing for the lung and renal injuries.